BioSpace News Archive

Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for rare and other high-burden diseases, today announced the closing of its public offering of 15,442,303 shares of its common stock at a public offering price of $4.75 per share

AMRA Medical and Pfizer will continue their collaboration to identify body composition biomarkers and phenotypes utilizing the UK Biobank resource

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on its website. This report, which is only for statutory purposes, can be accessed on QIAGEN’s website at: https://corporate.qiagen.com/investor-relations/financial-reports/other-reports QIAGEN N.V. further announc

Cambridge, MA-based clinical research organization to be responsible for Clinical Trial Site Management and On-Site Monitoring in the United States

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced it has been granted Orphan Drug Designation for SLS-005 in Sanfilippo syndrome from U.S. Food and Drug Administration..

In the race to find treatment options for COVID-19 patients, physicians and clinicians began treating the virus as they would viral pneumonia.

ViewRay, Inc. announced financial results for the first quarter ended March 31, 2020..

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2020.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter 2020 financial results after the market closes on Thursday, May 7, 2020.

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter ended March 31, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) commercial and development accomplishments, TUKYSA (tucatinib) U.S. Food and Drug Administration (FDA) approval and launch as well as progress with its lead programs to treat cancer.